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With the aim of assessing whether transition metal complexes might be utilized as efficient biocatalysts and
biological drugs, new monofunctional nickel(II) and copper(II) complexes of types NiL (1) and CuL (2) [H2L ¼
N-(N0,N0-diethylaminothiocarbonyl)benzimidoyl chloride-2-aminoacetophenone-N-methylthiosemicarba-
zone] were synthesized. The compounds are remarkably stable and were obtained in good yields.
Structural elucidation was carried out thoroughly in solid and solution-states by elemental analysis and
various spectroscopy techniques (IR, UV-vis, 1H NMR, and EPR) as well as ESI mass spectrometry. The
molecular structure of the compounds was investigated by single-crystal X-ray diffraction. The analyses
showed tetradentate coordination of the ligand in nickel(II) and copper(II) complexes, in which the metal
atom exhibits a square planar geometry with N2S2 in a donor fashion. Structural optimization, HOMO–
LUMO energy calculations and Natural Bond Orbital (NBO) analysis of H2L and its complexes (1 and 2)
were investigated by Density Functional Theory (DFT). The trend in binding affinities of the compounds
with biomolecules, such as calf thymus DNA (CT-DNA) and bovine serum albumin (BSA) protein, were
investigated by different spectrophotometric methods, which revealed an intercalative mode of
interaction. Furthermore, enzyme kinetic studies reflected that the square planar complexes (1 and 2) are
also effective in mimicking catecholase (3,5-DTBC) and phosphatase (4-NPP) activities over the parent
H2L. The high kcat values suggested that the selected compounds displayed a high rate of catalytic
efficiency. In vitro cytotoxicity of the complexes on human skin cancer melanoma (A375), human
cervical cancer (HeLa) and human hepatocellular carcinoma (Hep3B) cancer cell lines demonstrated that
the complexes had a broad-spectrum of anti-cancer activity with low IC50 values. The morphological
assessment data obtained by acridine orange/ethidium bromide (AO/EB) and diamidino-2-phenylindole
(DAPI) staining revealed that complex 2 induces apoptosis much more effectively than 1.ersity, Salem-636 011, India. E-mail:
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Ligand design is becoming an increasingly important part of
synthetic activity in chemistry. This is because of the subtle
control that ligands exert on the metal center to which they
are coordinated.1,2 Notably, the choice of hybrid ligands is
particularly crucial in the stabilization of highly reactive
species, promoting reactivity in unusual oxidation states3,4
and implementing catalytic as well as biological properties.5,6
Previously, many articles have shown that mono and biden-
tate ligand systems may have insufficient stability for in vitro
and in vivo studies, due to rapid ligand exchange reactions
with plasma components. However, many metal(II) cores
containing medium and so donor atom ligands were
particularly recommended for in vitro and in vivo studies.RSC Adv., 2015, 5, 103321–103342 | 103321
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View Article OnlineThus, chelators with a mixed sulfur and nitrogen donor
sphere might be very suitable for the formation of metal
complexes and some of them are used in medicinal appli-
cations.7 With the abovementioned fact in mind, tetradentate
N, S donor Schiff-base ligands have extensively been used as
supporting ligands in d-block chemistry because of their
ability to stabilize metals in different oxidation states.8,9
Thioureas are potentially very versatile ligands, as they are
able to coordinate to a range of metal centers as neutral
ligands, monoanions, or dianions. The effectiveness of
thiourea is believed to be due to the presence of a lone pair of
electrons in atoms, such as nitrogen, sulfur and oxygen and
p-electron clouds, which are capable of forming dative
covalent bonds with metals.10 Derivatives of thiourea such as
N-(dialkylaminothiocarbonyl)benzimidoyl chlorides were
rst synthesized and incorporated into the synthesis of the
corresponding benzamidines, which can readily be obtained
by reactions of benzimidoyl chlorides and primary amines,
with numerous metals that have been broadly studied.11
Benzamidines can be functionalized with an additional
donor group to modify the properties, depending on the
requirements. Thiosemicarbazones have been chosen to
functionalize benzimidoyl chlorides due to their versatile
coordination behavior and promising biological and phar-
maceutical properties.12–15 A new tetradentate chelator has
been synthesized from a benzimidoyl chloride moiety and N-
methylthiosemicarbazide (Scheme 1).
The discovery of cisplatin in 1965 was a major milestone
in cancer chemotherapy; cisplatin forms a Pt-DNA adduct
and ultimately inhibit cellular DNA transcription and repli-
cation. However, cisplatin causes side effects such as drug
resistance, and severe toxicity, for example, nephrotoxicity
and neurotoxicity.16–18 Therefore, new metal-based drugs
with novel mechanisms of action are being developed as an
alternative to platinum-based drugs. Numerous Co(III), Ni(II),
Cu(I/II), Zn(II) and Ru(II) complexes have been probed in the
quest for new inorganic drugs.19a–c Among the various met-
al(II) complexes, nickel and copper ions are considered as the
most promising alternatives to cisplatin as anticancer drugs
because they play an energetic role in biological functions
such as DNA, BSA, HSA and RNA interactions.19d
To nd highly effective, target-specic and less toxic
drugs, much effort has been devoted for the development of
metal-based anticancer agents that bind to DNA throughScheme 1 Synthetic route of H2L in this study.
103322 | RSC Adv., 2015, 5, 103321–103342a noncovalent interaction.20 There are three noncovalent
binding modes of metal complexes with DNA: electrostatic,
groove, and intercalation. Many important applications of
these complexes require that they can bind to DNA via an
intercalative mode that could induce cellular degradation.
Planarity of the ligand and the presence of aromatic systems
are factors that favor intercalation.21a Moreover, most of the
recent research on clinical agents has shown that drugs
(metal complexes) not only bind to the prime molecular
target, DNA, but also strongly interact with serum albumin
proteins such as BSA and HSA.21b It is essential to explore
drug–protein interactions as most of the drugs bound to
serum albumin are transported as a protein complex. Atten-
tion has also been focused on the proteins that drive and
control cell cycle progression.22
On the other hand, the catecholase/phosphatase-like
activities of some model coordination complexes have been
a topic of recent interest with respect to the development of
new bioinspired catalysts.23 Catechol oxidase is a copper-
containing type-III active-site protein (Scheme 2) that cata-
lyzes two-electron-transfer reactions during the oxidation of
a wide range of catechols, which is known as catecholase
activity, whereas hydrolase belongs to a class of metal-
loenzymes that catalyze the hydrolysis of several substrates,
including phosphate esters (4-NPP), peptides and nucleic
acids.24a To date, most researchers have focused on dinuclear
systems that structurally match the original enzyme, wherein
there exists a dimeric-copper active center. Recent investi-
gations have also shown that some manganese(II/III), nick-
el(II), zinc(II) and cobalt(II/III) species can also mediate suchScheme 2 Bio-active dimeric copper-containing type-III protein.
This journal is © The Royal Society of Chemistry 2015
Scheme 3 Synthesis of nickel(II) (1) and copper(II) (2) complexes.
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View Article Onlinecatechol oxidation.24b,c Therefore, much attention has been
focused on the catecholase/phosphatase-like properties of
benzamidine–thiosemicarbazone-containing nickel(II) and
copper(II) complexes.
Therefore, through the abovementioned contribution, we
reported the use of the ligand [N-(diethylaminothiocarbonyl)]-
benzimidoylchloride-2-aminoacetophenone-N-methylthiosemicar-
bazone] (H2L) in the synthesis of new nickel(II) and copper(II)
complexes (1 and 2) as shown in Scheme 3. Furthermore,
investigation of the binding properties of these complexes with
calf thymus DNA (CT-DNA) and BSA protein has been carried
out. Moreover, H2L and its complexes, 1 and 2, were also
investigated for possible catecholase- and phosphatase-like
activities. In addition, the cytotoxic activity of the new
compounds towards the normal Vero cell line, A375 (human
melanoma skin cancer), human cervical cancer (HeLa) and
human hepatocellular carcinoma (Hep3B) cell lines was evalu-
ated using MTT assay along with cell death analysis by AO/EB
and DAPI staining.Results and discussion
Synthesis and characterization
The benzamidine–thiosemicarbazone ligand, H2L, was synthe-
sized by the reaction of N-(diethylaminothiocarbonyl)benzimi-
doylchloride10with o-aminoacetophenone–thiosemicarbazone25
in the presence of the supporting base, Et3N. The syntheses of
nickel(II) and copper(II) complexes (1 and 2) were achieved in
good yields by the reaction of H2L with Ni(OAc)2$4H2O and
Cu(OAc)2$H2O, respectively (Scheme 3). In this reaction, H2L
acted as a dibasic tetradentate ligand in N2S2 fashion. The new
compounds under investigation are crystalline and nonhygro-
scopic solids, which are air-stable in solution and in the solid
state at room temperature, soluble in common organic solvents,
such as methanol, ethanol, benzene, chloroform, dichloro-
methane, acetone, dimethylsulfoxide, and dimethylformamide,
and insoluble in hexane, petroleum ether and diethyl ether. The
complexes have been characterized satisfactorily by elemental
analysis and IR, UV-vis, 1H-NMR and ESI-MS spectral studies. In
addition, the molecular structure of the ligand H2L and its
complexes, 1 and 2, was conrmed by single-crystal X-ray
crystallography.
IR spectroscopy has been used to conrm the deprotonation
and exact binding mode of the ligand. In the IR spectrum of theThis journal is © The Royal Society of Chemistry 2015ligand, three nNH bands were observed in the range of 3236–
3302 cm1.26 On complexation, the two nNH peaks disappeared,
indicating deprotonation of these groups in the ligand, and
a sharp band at 3390–3417 cm1 was assigned to the nNH stretch
of the H3C–NH–C–S group. A strong vibration was observed at
1668–1717 cm1 in the spectrum of the ligand, corresponding
to nC]N, which was shied to lower frequency in the complexes.
A sharp band at 838 cm1 was attributed to nC]S of the dieth-
ylaminothiocarbonyl moiety in H2L. This was shied to the
lower frequency region 784–790 cm1 in the complexes, indi-
cating participation of sulfur in the coordination. Furthermore,
one more band at 781 cm1 was assigned to nC]S, present in the
thiosemicarbazone part of H2L; this completely disappeared in
the spectra of the complexes and a new band at around 761–764
cm1 was assigned to nC–S, indicating thione–thiol tautomerism
of the –NH–C]S group and subsequent coordination of thio-
late sulfur aer deprotonation. These results clearly conrm
that coordination occurs through nitrogen and sulfur atoms.
The clearest characterization of the synthesized compounds
can be observed from the 1H-NMR spectra of ligand H2L and its
complex 1. The data are summarized in the experimental
section and the resulting spectra are depicted in Fig. S1 and S2.†
In the 1H NMR spectra, the signal due to the –NH hydrazinic
group of the ligand appeared at 12.72 ppm; this was absent in
the complex, supporting the ketoenolization and coordination
of the thiolate sulfur.27 The signal due to the Car–NH group,
which appeared at 8.47 ppm in the spectrum ofH2L, completely
disappeared in the spectrum of the complex, indicating
deprotonation upon complex formation. A signal at 8.10 ppm
was attributed to the NH–CH3 group of H2L; this was shied to
high eld at 4.85 ppm aer complexation.28 However, the
proton signals of the two methylene groups in H2L and its
complex 1, which should consequently be two quartets, appear
as four well-separated multiplet resonances at 3.74–4.12 ppm.6
This results in magnetic nonequivalence with respect to the
axial and equatorial positions of the four methylene protons, as
indicated by four separated signals with ABX3 splitting patterns
as previously reported.29,30 Furthermore, two triplet signals at
1.22–1.33 ppm for the methyl groups in N(CH2CH3)2 are
observed in the spectra of H2L and its complex 1.7 In addition,
the spectra of H2L and its complex 1 showed a series of over-
lapping multiplets for aromatic protons at 6.40–7.54 ppm.
UV-vis spectra of the complexes obtained in DMSO solution
(0–48 h) (Fig. S3†) are similar, suggesting that the complexesRSC Adv., 2015, 5, 103321–103342 | 103323
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View Article Onlineretain their structure in solution within the timeframe used for
the biological experiments. Electronic spectra of the
compounds displayed intense absorptions in the visible and
ultraviolet regions. The absorptions in the ultraviolet region are
assignable to transitions within the ligand orbitals. The bands
around 236–298 nm were assigned to ligand-centered (LC) p/
p* and n / p* transitions.15a The lowest energy absorption
maxima located in the 367–374 nm range may be assigned to an
S(pp) / M(dp) (M ¼ Ni2+, Cu2+) LMCT transition caused by
promotion of the electron from the full HOMO of the ligand of
primarily sulfur pp character to the empty LUMO of metal ion
dp character. Furthermore, the complexes showed broad bands
in the 431–491 nm region, which are attributed to d–d transi-
tions of spin-paired d8 (complex 1) and d9 (complex 2) species
with a square-planar structure (Fig. S3†). The geometry of the
complexes was further conrmed by single-crystal X-ray
diffraction analysis.
The EPR spectrum of complex 2 measured at 9.45 GHz (X-
band) corresponds to an axial g-tensor showing broad signals
(Fig. S4†). The g-parameters, gk and gt, were determined for
complex 2 but no coupling parameters could be extracted. The
averaged g-values (gav) were obtained through the relationship
between the anisotropic parameters of the g-tensors, from the
following expression: gav ¼ (gk + 2  gt)/3. Complex 2 exhibits
an anisotropic spectrum with gk ¼ 2.078, gt ¼ 2.031 and gav ¼
2.046, which is consistent with the presence of a square planar
geometry, as is evident from the crystal structure of 2. These
parameters are in good agreement with those of the related
square planar Cu2+ systems and are typical of axially symmet-
rical d9 copper(II) complexes15b (Fig. S4†).
The ESI-MS analyses of H2L and complexes 1 and 2 show the
most abundant peaks at m/z, 441.55, 498.42, and 503.52, which
were assigned to [M + H]+ ions. The molecular masses obtained
are in good agreement with the calculated molecular masses
(Fig. S5–S7†).Single-crystal X-ray diffraction studies
Single-crystal X-ray diffraction studies of the compounds (H2L, 1
and 2) conrm the conclusions drawn from the spectroscopy
studies. To gain insight into the coordination chemistry and
structural parameters of these compounds, good-quality single
crystals were isolated by slow evaporation of a concentrated
ethanol/dichloromethane solution and characterized by X-ray
diffraction. Details of the data collection, solution and rene-
ment are gathered in the experimental section and in Table 1.
ORTEP views of the molecular structures of compounds along
with partial atom numbering schemes are shown in Fig. 1–3 and
important bond lengths and angles for the compounds are
summarized in Table 2.
Fig. 1 depicts the molecular structure of H2L. H2L crystal-
lized in the triclinic Pi space group. Selected bond lengths and
angles are summarized in Table 2. The protonation of nitrogen
atoms N3 and N5 is experimentally justied by the detection of
peaks of electron density in the nal Fourier map, which can be
assigned to corresponding hydrogen atoms that are involved
in intermolecular hydrogen bonding. The N(3)–H(3)–S(1)103324 | RSC Adv., 2015, 5, 103321–103342hydrogen bond forms an intramolecular ring of type S11(6). The
C–N and C]N bond distances (see Table 2) found in H2L agree
well with those reported for other similar ligands containing C–
N/C]N bonds. The thione form is conrmed by the bond
lengths of C(1)–S(1) (1.704 A˚) and C(17)–S(2) (1.674 A˚), which are
very close to a formal C]S bond length (1.60 A˚). Examination of
the packing diagram of H2L revealed that the structure exhibits
intermolecular p–p stacking interactions between the parallel
C(9)–C(14) ring and its equivalent obtained by a (x, 1  y, z)
symmetry transformation, although the geometrical parameters
with a distance of 3.575 A˚ and a shi equal to 1.440 A˚ indicate
a rather weak interaction, as shown in Fig. S8.†
A perspective view of complexes 1 and 2 with the atomic
numbering schemes is depicted in Fig. 2 and 3, while selected
bond lengths and angles are given in Table 2. Complexes 1 and
2 crystallized in the triclinic Pbca space group. The metal ion
adopted a square planar geometry with H2L ligands bonded as
dibasic tetradentate (SNNS) donors. The trans angles are N(3)–
Ni(1)–S(2), 168.47(8) and N(4)–Ni(1)–S(1), 167.35(8) (for 1) and
N(3)–Cu(1)–S(2), 166.17(7) and N(4)–Cu(1)–S(1), 164.80(7) (for
2), which showed a deviation from the expected linear trans
geometry, suggesting distortion in the square-planar coordina-
tion geometry. The metal bond distances Ni–N and Ni–S in
complex 1 and Cu–N and Cu–S in complex 2 (Table 2) are in
good agreement with reported nickel(II) and copper(II) com-
plexes.31a,b Furthermore, there is intermolecular hydrogen
bonding between the atoms (C–H/N/S contact) of H2L and its
complexes, 1 and 2, as shown in Table 3. The unit cell packing
diagram of the compounds, along with hydrogen bonding, is
given in Fig. S9.†Theoretical calculations
HOMO and LUMO are referred to as frontier orbitals. The
energy difference between the HOMO and LUMO is termed as
the HOMO–LUMO energy gap. The difference in energy between
two frontier orbitals can be used to predict the strength and
stability of transition metal complexes as well as the colors they
produce in solution. Calculations using the density functional
theory (DFT) method of GAUSSIAN-09 were carried out to
determine the electronic structures of the compounds. A
molecule with a small gap is more polarized and is known as
a so molecule.32 Lowering of the HOMO–LUMO band gap is
essentially a consequence of stabilization of the LUMO due to
the strong electron-accepting ability of an electron-acceptor
group.
The molecular structure of H2L and the deprotonated forms
of its complexes 1 and 2 were characterized through computa-
tional studies of the solid phase. Contour plots of frontier
molecular orbitals of the complexes and the energy gap were
also calculated (Fig. 4). Positive and negative regions are shown
in red and blue, respectively, and the geometrical parameters
have already been given in Table 1. In general, there is good
correlation between the optimized structures and the X-ray
crystal structures of H2L and its complexes 1 and 2. The
perfect square planar geometries of the complexes are also re-
ected in their calculated structures. It is observed that in theThis journal is © The Royal Society of Chemistry 2015
Table 1 Crystal data and structure refinement for ligand H2L and its complexes 1 and 2
H2L 1 2
Empirical formula C22H28N6S2 C22H26N6NiS2 C22H26CuN6S2
Formula weight 440.62 497.32 502.15
Temperature (K) 100(2) K 295(2) K 295(2)
Wavelength (A˚) 0.71073 A˚ 0.71073 A˚ 0.71073 A˚
Crystal system Triclinic Orthorhombic Orthorhombic
Space group P1 Pbca Pbca
Unit cell dimensions
a (A˚) 7.831(6) A˚ 13.2007(7) A˚ 13.3637(4) A˚
b (A˚) 10.956(8) A˚ 17.5298(9) A˚ 17.6802(7) A˚
c (A˚) 14.357(18) A˚ 20.1722(11) A˚ 19.9696(6) A˚
a () 75.594(18) 90 90
b () 89.60(3) 90 90
g () 72.16(2) 90 90
Volume (A˚3) 1132.47(5) A˚3 4668.0(4) A˚3 4718.3(3) A˚3
Z 2 8 8
Density (calcd) mg m3 1.292 mg m3 1.415 mg m3 1.414 mg m3
Absorption coefficient 2.291 mm1 1.032 mm1 1.124 mm1
F(000) 468 2080 2088
Crystal size (mm3) 0.12  0.07  0.03 0.37  0.17  0.03 0.25  0.22  0.17
Theta range for data collection 3.18 to 73.12 3.44 to 25.04 3.608 to 25.07
Index ranges 9 # h # 8, 15 # h # 15 15 # h # 11
13 # k # 12 20 # k # 20 21 # k # 14
17 # l # 17 19 # l # 24 23 # l # 19
Reections collected 12 690 16 086 13 366
Independent reections 4299 [R(int) ¼ 0.0182] 4122 [R(int) ¼ 0.0666] 4158 [R(int) ¼ 0.0314]
Data/restraints/parameters 4299/0/275 4122/0/284 4158/0/284
Goodness-of-t on F2 1.132 1.059 1.049
Final R indices [I > 2 sigma(I)] R1 ¼ 0.0360, wR2 ¼ 0.1007 R1 ¼ 0.0440, wR2 ¼ 0.1096 R1 ¼ 0.0372, wR2 ¼ 0.0910
R indices (all data) R1 ¼ 0.0364, wR2 ¼ 0.1011 R1 ¼ 0.0607, wR2 ¼ 0.1180 R1 ¼ 0.0511, wR2 ¼ 0.0968
Table 2 Selected bond lengths (A˚) and bond angles () for H2L and its complexes, 1 and 2, with the optimized geometrical values
H2L X-ray DFT 1 X-ray DFT 2 X-ray DFT
C(1)–N(1) 1.339(2) 1.358 N(3)–Ni(1) 1.872(2) 1.890 N(3)–Cu(1) 1.932(2) 1.954
C(1)–S(1) 1.704(2) 1.784 S(1)–Ni(1) 2.149(9) 2.262 S(1)–Cu(1) 2.244(7) 2.365
C(1)–N(2) 1.362(2) 1.371 N(4)–Ni(1) 1.900(2) 1.911 N(4)–Cu(1) 1.981(2) 1.997
C(2)–N(2) 1.309(2) 1.325 S(2)–Ni(1) 2.157(9) 2.276 S(2)–Cu(1) 2.230(9) 2.361
C(2)–N(3) 1.333(3) 1.356 N(3)–C(6) 1.353(3) 1.354 N(3)–C(2) 1.353(3) 1.367
C(9)–N(3) 1.418(2) 1.428 N(3)–C(13) 1.409(3) 1.419 N(3)–C(9) 1.400(3) 1.412
C(15)–N(4) 1.274(2) 1.301 N(4)–C(19) 1.319(4) 1.315 N(4)–C(15) 1.308(4) 1.314
C(17)–N(5) 1.354(2) 1.386 S(2)–C(21) 1.729(3) 1.805 S(2)–C(17) 1.739(3) 1.808
C(17)–N(6) 1.323(2) 1.338 S(1)–C(1) 1.717(3) 1.789 S(1)–C(1) 1.720(3) 1.789
C(17)–S(2) 1.674(2) 1.730 N(2)–C(6) 1.306(4) 1.339 N(2)–C(2) 1.308(3) 1.335
N(1)–C(1)–S(1) 120.5(1) 120.1 N(3)–Ni(1)–N(4) 93.5(1) 92.0 N(3)–Cu(1)–N(4) 92.22(9) 91.9
C(2)–N(3)–H(3) 116.3(1) 113.2 N(4)–Ni(1)–S(2) 87.48(2) 86.7 N(4)–Cu(1)–S(2) 86.67(7) 85.7
C(15)–N(4)–N(5) 118.5(1) 119.6 S(2)–Ni(1)–S(1) 85.65(3) 88.9 S(2)–Cu(1)–S(1) 89.58(3) 90.5
N(6)–C(17)–S(2) 122.8(1) 125.7 N(3)–Ni(1)–S(1) 95.32(7) 92.4 N(3)–Cu(1)–S(1) 94.83(7) 92.4
N(5)–C(17)–S(2) 120.6(1) 118.5 N(3)–Ni(1)–S(2) 168.47(8) 173.0 N(3)–Cu(1)–S(2) 166.17(7) 169.8
C(9)–N(3)–H(3) 116.3(1) 116.6 N(4)–Ni(1)–S(1) 167.35(8) 175.3 N(4)–Cu(1)–S(1) 164.80(7) 174.2
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View Article Onlinecomplexes, the electron density of the HOMO is localized largely
on the atoms (N and S) surrounding the metal ion and to
a much smaller extent on the ligand, whereas in the LUMO,
major contributions are from the ligand and to a lesser extent
from the atoms surrounding the metal ion. Therefore, electron
transfer occurs from the highest occupied molecular orbital
(HOMO) to the lowest unoccupied molecular orbital (LUMO). ItThis journal is © The Royal Society of Chemistry 2015can be inferred that electron transfer in complexes is related to
LMCT. The calculated HOMO energies of the complexes vary as
H2L (5.68 eV) < 1 (5.25 eV) < 2 (5.31 eV) and those of the
LUMO exhibit a similar trend: H2L (2.04 eV) < 1 (2.15 eV) < 2
(2.05 eV). The HOMO–LUMO energy gaps in H2L (3.64 eV),
complex 1 (3.12 eV) and complex 2 (3.20 eV) are only slightly
different and their order is consistent with the experimentallyRSC Adv., 2015, 5, 103321–103342 | 103325
Fig. 1 Perspective view (25% probability ellipsoids) of H2L with the atom numbering scheme.
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View Article Onlineobserved order of the biological efficiencies of the complexes.
The calculated atomic charges and electronic congurations of
donor atoms and metal-centered atoms are listed in Table 4.Fig. 2 Perspective view (25% probability ellipsoids) of complex 1 with th
103326 | RSC Adv., 2015, 5, 103321–103342From Table 4, it can be observed that the electron pop-
ulations on the s and p orbitals of nitrogen and sulfur donor
atoms in both complexes are less than the expected values ofe atom numbering scheme.
This journal is © The Royal Society of Chemistry 2015
Fig. 3 Perspective view (25% probability ellipsoids) of complex 2 with
the atom numbering scheme.
Table 3 Hydrogen bonds for H2L and its complexes, 1 and 2
a [A˚ and ]
Compound D–H/A d(D–H) d(H/A) d(D/A) :(DHA)
H2L N(3)–H(3)–S(1) 0.86 2.28 2.968(2) 137.2
N(5)–H(5)–S(2) 0.86 2.61 3.351(2) 145.2
N(6)–H(6)–N(4) 0.86 2.19 2.577(2) 106.9
1 C(2)–H(2A)–S(1) 0.97 2.57 2.963(3) 104.3
C(20)–H(20A)–N(5) 0.96 2.24 2.600(5) 101.2
2 C(16)–H(16B)–N(5) 0.96 2.21 2.611(4) 103.9
C(19)–H(19B)–S(1) 0.97 2.56 2.949(3) 104.2
a Symmetry operation: H2L: ‘x, y, z’; ‘x, y, z’, complex 1: ‘x, y, z’; ‘x
+ 1/2, y, z + 1/2’; ‘x + 1/2, y + 1/2, z’; ‘x, y + 1/2, z + 1/2’; ‘x, y,
z’; ‘x  1/2, y, z  1/2’; ‘x  1/2, y  1/2, z’; ‘x, y  1/2, z  1/2’,
complex 2: ‘x, y, z’; ‘x + 1/2, y, z + 1/2’; ‘x + 1/2, y + 1/2, z’; ‘x, y
+ 1/2, z + 1/2’; ‘x, y, z’; ‘x  1/2, y, z  1/2’; ‘x  1/2, y  1/2,
z’; ‘x, y  1/2, z  1/2’ [D ¼ donator, A ¼ acceptor].
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View Article Onlinevalence orbitals, whereas the computed electron population in
the central ion in both complexes 1 and 2 is more than the ex-
pected value in M2+ (Ni, Cu) with d8 and d9 electronic congu-
rations, respectively.33 The calculated formal charges on the
metal ions (1 ¼ 0.954 eV; 2 ¼ 1.195 eV) in the complexes were
lower than the formal charge of +2, conrming a signicant
charge donation from the ligand, H2L. This conrms electron
transmission from donor atoms toward the central metal. The
calculated electronic congurations (Table 4) of the donor
atoms with reference to s and p orbitals are consistent with
electron donation towards the metal ion.DNA interaction studies
Stability of compounds. Before carrying out DNA binding
studies, the stability of the complexes is paramount with respectThis journal is © The Royal Society of Chemistry 2015to their application. The stability of the selected compounds
(H2L, 1 and 2) has been determined in Tris–HCl buffer (5 mM
Tris–HCl-50 mM NaCl buffer, pH ¼ 7.2) at four different time
points (0 min, 1 h, 6 h and 12 h) using the UV absorption
method. The UV-vis spectral results did not reveal any appre-
ciable change in either the intensity or the position of the
absorption bands in Tris–HCl buffer solution (Fig. S3†). This
demonstrates that the compounds are stable under physiolog-
ical conditions.
Fluorescence emission titration. DNA is oen a vital target to
mediate cell apoptosis or necrosis. Therefore, the binding
affinity of themetal complexes to CT-DNA was used as a primary
criterion for assessing their suitability as chemotherapeutic
agents. These studies were carried out using different spectral
methods. As a basic testing method, uorescence spectroscopy
is one of the most commonly-used techniques for exploring the
interaction of any drug with CT-DNA.34 This technique is
commonly used to study the binding mode (and its nature)
between DNA and metal complexes. Emissive titration experi-
ments were performed by monitoring the changes in emission
intensity as a result of aliquot addition of DNA. Usually, inter-
calative modes of interaction between metal complexes and
DNA result in hypochromism with or without red/blue shi; on
the other hand, non-intercalative/electrostatic interaction cau-
ses hyperchromism. Therefore, typical emissive titration curves
for the selected compounds in the absence and presence of CT-
DNA at different increasing concentrations were implemented.
From the emissive titration spectra (Fig. 5), it is apparent
that the addition of an increasing concentration of CT-DNA (0–
50 mM) to a solution of H2L resulted in hypochromism (2.41%)
at 304 nm along with a small red shi (2 nm). Complexes 1
and 2 show different behavior relative to that of the ligand and
exhibit bands at 406 and 528 nm, showing hypochromism of
about 36.36% and 53.27%, respectively, with a small red shi
(4 nm). The observed hypochromism is due to an intercalative
mode of binding involving a strong stacking interaction
between the extended aromaticity of the ligand and the base
pairs of DNA.35 The binding of compounds to DNA leads to
hypochromism, which provides a measure of the strength of the
intercalative binding. Based on the emission enhancement, the
intrinsic binding constant was obtained according to the
Scatchard equation:
Cb ¼ Ct(F – F0)/(Fmax  F0),
where Ct is the total compound concentration, F is the observed
uorescence emission intensity at a given DNA concentration,
F0 is the intensity in the absence of DNA and Fmax is the uo-
rescence of the totally bound compound. The uorescence
spectra of the tested compounds with an increasing concen-
tration of CT-DNA are depicted in Fig. 5. Intrinsic binding
constants (Kb) were cast in the form of a Scatchard plot of r/Cf
versus r, where r is the binding ratio of Cb/[DNA] and Cf is the
free ligand concentration. The intrinsic binding constants (Kb)
for the interaction of H2L, 1 and 2 with CT-DNA are listed in
Table 5. The binding constants (Kb) of the compounds were in
the range of 4.30  103 to 8.50  104 M1. However, theRSC Adv., 2015, 5, 103321–103342 | 103327
Fig. 4 Frontier molecular orbitals of compounds, their HOMO–LUMO energy gap and their B3LYP/6-311G ground state optimized geometry
(top).
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View Article Onlinecomplexes interact with CT-DNA more strongly than the ligand
does. The observed values of Kb revealed that the compounds
bind to DNA via an intercalative mode, where the order of DNA-
binding affinity is 1 > 2 > H2L. However, the binding mode
needs to be conrmed through some more experiments.
Ethidium bromide displacement study. Fluorescence-
quenching experiments with EB-bound DNA were under-
taken to understand the mode of DNA interaction with the
metal complexes. The molecular uorophore, EB, emits103328 | RSC Adv., 2015, 5, 103321–103342intense uorescence at about 600 nm in the presence of DNA
due to its strong intercalation with adjacent DNA base
pairs.36 Addition of a second molecule, which binds to DNA
more strongly than EB, (the uorescence intensity of EB
increases by almost 20-fold aer binding to DNA) would
displace the bound EB and quench the DNA-induced EB
emission. The extent of quenching of the uorescence of the
EB bound to DNA would reect the extent of DNA binding of
the second molecule.37 Keeping the abovementioned fact inThis journal is © The Royal Society of Chemistry 2015
Table 4 Charges (a.u.) and electronic configurations of atoms for complexes 1 and 2
Atom
Complex 1 Complex 2
Charge (eV) Electronic conguration Charge (eV) Electronic conguration
Ni/Cu 0.95397 [Core]4S(0.41)3d(8.60)4p(0.02)5S(0.02) 1.19451 [Core]4S(0.43)3d(9.35)4p(0.01)5S(0.01)
N1(6) 0.65053 [Core]2S(1.32)2p(4.31)3p(0.01) 0.72124 [Core]2S(1.33)2p(4.37)3p(0.01)
N2(7) 0.37386 [Core]2S(1.35)2p(4.00) 3p(0.02) 0.42138 [Core]2S(1.36)2p(4.04)3p(0.02)
S1(2) 0.28649 [Core]3S(1.80)3p(4.47)4S(0.01)4p(0.01) 0.34276 [Core]3S(1.81)3p(4.52)4S(0.01)4p(0.01)
S2(3) 0.36154 [Core]3S(1.81)3p(4.53)4p(0.01) 0.42362 [Core]3S(1.82)3p(4.58)4S(0.01)4p(0.01)
C1(11) 0.34264 [Core]2S(0.86)2p(2.77)3p(0.02) 0.34451 [Core]2S(0.86)2p(2.77)3p(0.02)
C2(39) 0.31027 [Core]2S(0.86)2p(2.79)3S(0.01)3p(0.03) 0.30966 [Core]2S(0.87)2p(2.79)3S(0.01)3p(0.03)
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View Article Onlinemind, as the concentration of H2L and its complexes, 1 and 2,
increased, the emission band at 604 nm (Fig. 6) for EB
exhibited hypochromism up to 26.97%, 47.95% and 31.41%,
respectively, with a slight red/blue shi from the initial
uorescence. The quenching of the emission intensity ofFig. 5 Fluorescence titrations of H2L, 1 and 2 (25 mM) with CT-DNA (0–
(right).
This journal is © The Royal Society of Chemistry 2015ethidium bromide on addition of these compounds shows
that the complexes probably compete with EB for binding
with DNA. Further quantitative assessment of the magnitude
of interaction was ascertained by the classical Stern–Volmer
equation:50 mM) (left). Scatchard plots of r/Cf vs. r for the selected compounds
RSC Adv., 2015, 5, 103321–103342 | 103329
Table 5 Fluorescence spectral parameters for compounds H2L, 1 and
2 bound to CT-DNA
Compound Kb Ksv Kapp
H2L 4.30  103 9.3  103 8.01  103
1 8.50  104 1.82  104 3.21  105
2 4.49  104 2.17  104 3.45  105
RSC Advances Paper
Pu
bl
ish
ed
 o
n 
18
 N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
w
er
sy
te
t S
la
sk
i o
n 
09
/1
2/
20
15
 1
8:
42
:2
0.
 
View Article OnlineI0/I ¼ 1 + Ksv[Q]
where I0 and I are the emission intensities of EB-bound CT-DNA
in the absence and presence of quencher (complexes) concen-
tration [Q], respectively, which gave the Stern–Volmer quench-
ing constant (Ksv). Ksv was obtained from the slope of a plot of I0/
I versus [Q], as shown in Fig. 6. The quenching constant (Ksv)
values obtained indicated that the complexes strongly bind to
DNA. These are listed in Table 5.Fig. 6 Fluorescence titrations of H2L, 1 and 2 (0–50 mM) with EB-bou
compounds (right).
103330 | RSC Adv., 2015, 5, 103321–103342Furthermore, the apparent DNA binding constants (Kapp)
were also calculated using the following equation:
KEB[EB] ¼ Kapp[M50%]
where KEB ¼ 1.0  107 M1 is the DNA binding constant of EB,
[EB] is the concentration of EB (7.5 mM) and [M50%] is the
concentration of the compound used to obtain a 50% reduction
in the uorescence intensity of DNA pretreated with EB. The
Kapp values for the ligand and complexes 1 and 2 are given in
Table 5. The DNA binding ability of the compounds follows the
order 1z 2 >H2L, which is consistent with the results, obtained
from the abovementioned uorescence spectral studies.
Viscosity measurement. This technique gives us useful
information on how the conformation of DNA is inuenced by
the binding mode of the metal complex to DNA. In general, the
viscosity of CT-DNA increases when a compound binds withnd CT-DNA (7.5 mM) (left). Scatchard plots of I0/I vs. Q for selected
This journal is © The Royal Society of Chemistry 2015
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View Article OnlineDNA in intercalating mode but remains unchanged when
a compound binds with DNA in electrostatic mode.38 WhenH2L
and its complexes, 1 and 2, were treated with CT-DNA (200 mM),
as the concentrations of the compounds (0–120 mM) increased
from a ratio of r ¼ 0–0.1(1/r ¼ [compound]/[DNA]), the relative
viscosity of DNA enlarged steadily in the order 2 > 1 > H2L. The
relative viscosity of DNA solution increases upon addition of all
the compounds and it is more pronounced in the case of the
complexes (Fig. 7). The observed behavior of the DNA viscosity
upon addition of the compounds may be considered as
evidence of the existence of an intercalative binding mode to
DNA, a conclusion that claries the preliminary indications
derived from uorescence spectroscopy studies.BSA interaction studies
Fluorescence spectral study. Interactions between complexes
and the most abundant blood protein, bovine serum albumin,
have attracted immense current interest because of its struc-
tural homology with human serum albumin.39a To understand
the mechanism of interactions between the selected
compounds and BSA, uorescence quenching experiments have
been carried out. The uorescence spectra of BSA showed
a broad band with a maximum at 340 nm. The relative ratios
of uorescence intensity for three amino acids and their func-
tions were reported earlier.33 Therefore, the uorescence
behavior of BSA can provide signicant information about its
structure, dynamics, and protein folding. A solution of BSA
(1 mM) was titrated with various increasing concentrations of
compounds H2L, 1 and 2 (0–50 mM) in the wavelength range of
290–430 nm (lex¼ 280 nm). Fig. 8 shows the effect of increasing
concentration of compounds on the uorescence emission of
BSA.Fig. 7 Relative viscosity (h/h0)
1/3 of CT-DNA in Tris–HCl buffer solu-
tion in the presence of tested compounds at increasing concentra-
tions (r ¼ 0–0.1).
This journal is © The Royal Society of Chemistry 2015The extent of quenching of uorescence intensity, as
expressed by the Stern–Volmer constant (Ksv), is a measure of
the protein binding affinity of the complexes. To gain an insight
into the quenching progression, the quenching constant (Kq)
was evaluated from the following Stern–Volmer equation:
I0/I ¼ 1 + Ksv[Q] ¼ 1 + Kqso[Q]
where I0 and I are the uorescence intensities in the absence
and presence of the quencher, respectively, Kq is the
quenching rate constant, so is the uorescence life time of
biopolymer BSA (so ¼ 108 s),39b and Ksv and [Q] are the Stern–
Volmer quenching constant and the concentration of the
quencher, respectively. The quenching constant (Kq) was
obtained from a plot of log(I0  I)/I versus log[Q] (Fig. 8). It
can be observed that the Kq value of BSA is higher than 1.0 
1012, which is much higher than the molecular uorescence
diffusing constant, as shown in Table 6. Therefore, the uo-
rescence quenching mechanism of the compounds-BSA
system cannot be dynamic quenching. It may be static
quenching. Nevertheless, the hypothesis needs to be proved
through some more experiments.
UV-visible spectral study. It has been proved that the uo-
rescence quenching mechanism of the compound is static
quenching by UV-vis absorption spectral studies. The uo-
rescence quenching mechanisms are usually classied as
either static or dynamic quenching. Static quenching usually
results from the formation of a complex between the
quencher and the uorophore in the ground state, whereas in
dynamic quenching the uorophore and the quencher come
into contact with each other during the transient existence of
the excited state.40 UV-visible absorption spectroscopy is an
effective method of identifying the type of quenching. UV-
visible spectra of BSA in the absence and presence of the
compounds (Fig. 9) showed that the absorption intensity of
BSA was enhanced as the complexes were added and there
was a small blue shi. It was also revealed that there existed
a static interaction between BSA and the added complexes
due to the formation of a ground state complex of the type
BSA-compound.
Binding constant and binding site number. The binding
constant Kbin was calculated using the Scatchard equation
log[I0  I/I] ¼ log Kbin + n log[Q],
where Kbin is the binding constant of the compound with BSA
and n is the number of binding sites. The number of binding
sites (n) and the binding constant (Kbin) have been found from
the plot of log(I0 I)/I versus log[Q] (Fig. 8).41 The calculated Kbin
and n values are given in Table 6. The calculated value of n is
around 2, indicating the existence of two binding sites in BSA
for all the compounds. The higher values of Kq and Kbin indicate
a strong interaction between the BSA protein and the complexes
compared to the ligand used in this study. It is noted that the
binding constants of the compounds follow the order 2 > 1 >
H2L, which is consistent with the results obtained from the
abovementioned binding affinity studies.RSC Adv., 2015, 5, 103321–103342 | 103331
Fig. 8 Fluorescence titrations of H2L, 1 and 2 (0–50 mM) with BSA (1 mM) (left). Stern–Volmer plots of I0/I vs. Q and Scatchard plots of log[I0 I/I]
vs. log[Q] for selected compounds (right).
Table 6 Quenching parameters of BSA for compounds H2L, 1 and 2
Compound Ksv Kq Kbin ‘n’
H2L 1.83  105 1.83  1013 6.05  107 1.5
1 1.19  105 1.19  1013 1.34  109 1.9
2 1.02  105 1.02  1013 1.44  109 1.8
103332 | RSC Adv., 2015, 5, 103321–103342
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View Article OnlineCatechol oxidase activity
3,5-Di-tert-butylcatechol (3,5-DTBC) was employed as
a substrate to study the catalytic performance of H2L and its
complexes, 1 and 2, mainly because its low reduction potential
makes it easy to oxidize and the bulky tert-butyl groups prevent
further oxidation such as ring opening and it has shown a low
quinone–catechol reduction potential (Scheme 4).42 TheThis journal is © The Royal Society of Chemistry 2015
Fig. 9 Absorbance spectra of the compounds H2L, 1 and 2 with BSA.
Scheme 4 Catalytic oxidation of 3,5-DTBC to 3,5-DTBQ in DMSO in
the presence of oxygen.
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View Article Onlinereactions were carried out at room temperature in aerobic
conditions and were monitored by uorescence spectroscopy.
Moreover, the oxidation product of 3,5-di-tert-butylbenzoqui-
none (3,5-DTBQ) is highly stable and exhibited a characteristic
emission intensity at lemis ¼ 437 nm (lex ¼ 401 nm) in pure
DMSO. To monitor the reaction, 1  104 M solutions of the
selected compounds were treated with 100 equivalents of 3,5-
DTBC. Upon addition of the catecholic substrate, a new band
(Fig. 10) gradually appeared at about 437 nm due to the
formation of the oxidized product, 3,5-DTBQ. Thus, the exper-
iment clearly proves that the oxidation of 3,5-DTBC to 3,5-DTBQ
is catalyzed by the synthesized compounds, as it is well estab-
lished that 3,5-DTBQ shows a maximum at lemis ¼ 437 nm in
pure DMSO.
Kinetic study of the catecholase activity
To understand the kinetic aspects of catalysis for the tested
compounds, the rate constants for the compounds as cata-
lysts were determined by traditional initial rate methods
(detailed description provided in the Experimental section).
The catalytic behavior shows saturation kinetics and a treat-
ment based on the Michaelis–Menten model seemed to be
appropriate under excess substrate conditions.43a The
observed rate constants (ki) were extracted by the initial rate
method. Plots of ki vs. [3,5-DTBC] gave non-linear curves with
decreasing slopes (Fig. S10†), which are best described by the
following equations.This journal is © The Royal Society of Chemistry 2015Cþ S) *k1
k2
CS) *
k2
k2
Cþ P
V ¼ Vmax½S
KM þ ½S
1
V
¼ KM
Vmax
1
½S þ
1
Vmax
A plausible mechanism for 3,5-DTBC oxidation promoted by
metal(II) complexes is depicted in Scheme 5. Unfortunately, we
were unable to characterize the intermediates. However, when
a mixture of starch and potassium iodide solution was added to
a mixture of complex and 3,5-DTBC, a blue coloration developed,
indicating that hydrogen peroxide was produced during the course
of the reaction. It is interesting to note that no blue coloration was
observed in the absence of 3,5-DTBC. A believable mechanistic
path for the formation of H2O2 as a by-product during the oxida-
tion of 3,5-DTBC to 3,5-DTBQ, catalyzed by metal(II) compounds,
was suggested by Chyn and Urbach.43b
According to the reported plausible mechanism for the gener-
alized catecholase reaction (Scheme 5), electron transfer is mainly
assisted by the metal center and then further delocalized via the
C]N bond of metal(II) complexes to the adjacent conjugate
system. Particularly, the chelate formation of complexes extended
by aromatic system containing delocalised p-electron cloud and
the probable thione–thiol tautomerism showed in Scheme 3. The
Michaelis–Menten constant (Km) and the maximum initial rate
(Vmax) were determined by linearization using Lineweaver–Burk
plots (Fig. 10). The rate constants for dissociation of substrates S
(i.e. turnover number, kcat) were calculated from the graphs of 1/V
vs. 1/[S] (Fig. 10), known as the Lineweaver–Burk graph, using the
abovementioned equation and all these parameters are listed in
Table 7. Upon comparison of the values in Table 7, it may be stated
that complexes 1 and 2 are highly efficient catalysts, wherein the
order of their activity is 2 > 1 > H2L.
Phosphate hydrolysis activity
Many metalloenzymes with hydrolytic properties contain metal
ions in close proximity to the active site. The selected compounds
meet the prerequisites for use as a functional model system for
hydrolytic enzymes. To study the phosphatase activity of
compounds, 4-nitrophenyl phosphate disodium salt hexahydrate
(4-NPP) (Scheme 6) was the preferred choice of substrate.44 Its
hydrolytic tendency was detected bymonitoring the time evolution
of the p-nitrophenolate ion (4-NP) in DMSO using emission
intensities at lemis¼ 436 nm (lex¼ 401 nm) over a wavelength scan
of 400–800 nm over 2 hours with 40 equivalents of the substrate
being used relative to the catalyst.
Kinetic study of the phosphatase activity
Kinetic studies of compounds were carried out using the initial-
slope method by monitoring the rate of the increase in the emis-
sive intensity band at 423 nm, which corresponds to the increaseRSC Adv., 2015, 5, 103321–103342 | 103333
Fig. 10 Oxidation of 3,5-DTBC by H2L and complexes 1 and 2, monitored by fluorescence spectroscopy (left). Lineweaver–Burk plot for tested
compounds (right).
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View Article Onlinein the concentration of 4-nitrophenolate.45 The catalytic behavior
shows saturation kinetics and a treatment based on theMichaelis–
Menten model seemed to be appropriate under excess substrate
conditions.46 The observed rate constants (ki) were extracted by the
initial rate method. Plots of ki vs. [4-NPP] gave non-linear curves
with decreasing slopes (Fig. S11†), which are best described by the
kinetics of the catecholase equation. Understandably, the reaction
displays rst-order kinetics at lower concentrations and gradually
differs fromunity at higher concentrations. TheMichaelis–Menten
constant (Km) and the maximum initial rate (Vmax) were deter-
mined by linearization using Lineweaver–Burk plots (Fig. 11). The
rate constants for dissociation of substrates S (i.e. turnover103334 | RSC Adv., 2015, 5, 103321–103342number, kcat) were calculated from the graphs of 1/V vs. 1/[S]
(Fig. 11), known as Lineweaver–Burk graphs, using the kinetics
equation; all these parameters are listed in Table 8. The results
indicate rst-order rate constant values, which are comparable to
the reported values for phosphate bond cleavage.47 The order of
their catalytic activity is 2 > 1 > H2L.Anticancer activity in vitro
Inhibition of cancer cell viability (MTT assay). The anti-
proliferative activities of H2L and complexes 1 and 2 were
appraised against the normal Vero cell line, the humanThis journal is © The Royal Society of Chemistry 2015
Scheme 5 Plausible mechanism for oxidation of 3,5-DTBC by complexes 1 and 2.
Scheme 6 Catalytic hydrolysis of 4-nitrophenyl phosphate disodium
salt hexahydrate (4-NPP) to the 4-nitrophenolate ion (4-NP) in DMSO.
Table 7 Kinetic parameters for the catecholase activity of H2L and
complexes 1 and 2
Catalyst Km (M) Vmax (Mm
1) Kcat (h
1)
H2L 9.16  103 3.64  104 91.3
1 1.12  102 5.25  104 116
2 1.46  102 9.17  104 146
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinemelanoma skin cancer cell line (A375), human cervical cancer
(HeLa) and the human hepatocellular carcinoma (Hep3B)
cancer cell line using the MTT assay. Cisplatin was used as the
reference compound to evaluate the cytotoxic activity. Cells were
exposed to a broad range of drug concentrations (10–100 mg
mL1) for 24 h and cell viability was analyzed by colorimetric
MTT assay.48 The results were analyzed by cell viability curves
and expressed with IC50 values ofH2L and its complexes, 1 and 2
(Table 9). The amount of cell proliferation signicantly
decreased in a dose-dependent manner on supplementation
with the selected compounds (H2L, 1 and 2), as observed within
24 h of incubation with the normal Vero and cancer cell line,
such as A375, HeLa and Hep3B, because thiosemicarbazones
are known inhibitors of enzyme ribonucleotide diphosphate
reductase (RDR).49 RDR is responsible for maintaining
a balanced supply of dNTPs, which are required for DNA
synthesis and repair and play an important role in cell prolif-
eration. The ligandH2L expressed moderate cytotoxicity against
normal and cancer cell lines. As can be observed, the results of
MTT assays revealed that the compounds show notable activityRSC Adv., 2015, 5, 103321–103342 | 103335
Fig. 11 Hydrolysis of 4-NPP by H2L and complexes 1 and 2, monitored by fluorescence spectroscopy (left). Lineweaver–Burk plots for tested
compounds (right).
Table 8 Kinetic parameters for the phosphatase activity of H2L and
complexes 1 and 2
Catalyst Km (M) Vmax (Mm
1) Kcat (h
1)
H2L 9.38  102 3.89  103 1876
1 10.2  102 4.53  103 2040
2 2.54  101 1.15  102 5080
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View Article Onlineagainst cancer cell lines (A375, HeLa, Hep3B) with low IC50
values (Fig. 12). Moreover, when we compare these observa-
tions, we can observe that the coordination of a metal to the
ligand increased its cytotoxic activities. Upon conrmation of103336 | RSC Adv., 2015, 5, 103321–103342their excellent cytotoxicity properties, further staining assays
were performed to determine their mechanism of action.
Cell morphological observation for apoptosis induction. To
determine the mode of cell death, cells were grown on cover-
slips, treated with the compounds for 24 h (Fig. 13) and
observed for changes inmorphology. Apoptosis is the process of
programmed cell death (PCD) that occurs in multicellular
organisms. These morphological changes include blebbing, cell
shrinkage, nuclear fragmentation, chromatin condensation,
chromosomal DNA fragmentation and global mRNA decay.50
Cell death apoptosis in the A375, HeLa and Hep3B cell lines
induced by complexes 1 and 2 was primarily studied with
respect to the changes observed in the cell morphology aer theThis journal is © The Royal Society of Chemistry 2015
Fig. 12 IC50 values of compounds H2L, 1 and 2 on normal Vero and
cancer cell lines such as A375, HeLa and Hep3B.
Table 9 In vitro cytotoxicity of the compounds in normal and cancer
cell lines
Compound
IC50
a (mg mL1)
Vero A375 HeLa Hep3B
H2L 72.92  2.67 56.64  1.69 84.14  0.89 64.56  1.24
1 58.92  1.44 26.64  2.37 15.17  2.03 14.47  2.31
2 59.62  1.02 28.88  1.85 12.83  1.65 11.36  1.57
Cisplatinb NDc 12.10  0.6 13.00  2.01 NDc
a Fiy percent inhibitory concentration aer exposure for 48 h in the
MTT assay. b Data from ref. 33 and 49. c No data.
Fig. 13 Images of drug-treated A375, HeLa and Hep3B cancer cells after
at fixed concentrations. The yellow arrows show early apoptotic cells w
necrotic cells.
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinecells were stained. Apoptotic cells exhibit increased plasma
membrane permeability to certain uorescent dyes, e.g. AO/EB,
Hoechst, AO/PI and DAPI.51 In this study, we have used
membrane-permeable AO/EB and DAPI uorescence staining.
Images of the control cells and treated A375, HeLa and
Hep3B cancer cells are depicted in Fig. 13. In this gure, yellow
arrow(s) show early apoptotic cells with membrane blebbing,
which is observed at xed doses (10 mg mL1) of the complexes,
and blue arrow(s) exhibited late apoptotic cells with chromatin
aggregation, that is, highly condensed chromatin. The red
arrow(s) show necrotic cells. These are the characteristic
features of apoptotic cells and are quite different from those of
the control cells. Overall, the results indicate that the complexes
favor necrosis at a xed lower dose, which is in good agreement
with the reported toxicity results.52Conclusion
Two new metal(II) [M ¼ Ni2+ (1), Cu2+ (2)] complexes have been
designed and synthesized using a doubly deprotonated N2S2
hybrid benzamidine–thiosemicarbazone ligand. The charac-
terization of the compounds was accomplished by elemental
analysis and various spectroscopy techniques (IR, UV-vis and 1H
NMR) as well as ESI mass spectrometry. The solid state struc-
ture of all the compounds was conrmed by single-crystal X-ray
crystallography. The geometry of complexes 1 and 2 revealed
a square-planar arrangement around the metal ion. On the
basis of DFT studies, the HOMO–LUMO energy gap explained
the charge transfer interactions occurring within the molecule.
The lowering of the HOMO–LUMO band gap supported the
bioactive properties of the molecule. The structural parameters
of the complexes, which are in good agreement with X-ray
analysis, were obtained by DFT calculations. The CT-DNAAO/EB and DAPI staining, followed by 24 h incubation with complexes
ith blebbing, blue arrows show late apoptosis and red arrows show
RSC Adv., 2015, 5, 103321–103342 | 103337
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View Article Onlinebinding propensities of the compounds were determined by
various physico-chemical techniques. All the experimental
results showed that the complexes interact strongly with CT-
DNA by an intercalative binding mode. Furthermore, the
results of uorescence quenching experiments with BSA
conrmed that the complexes have binding affinity in static
mode. Apart from the abovementioned interactions, the
compounds showed effective bio catalytic activity toward the
oxidation of 3,5-DTBC and the hydrolysis of 4-NPP. The
complexes showed widespread anti-tumor potency with low IC50
values tested by MTT assay against the normal Vero cell line and
skin (A375), cervical (HeLa) and liver (Hep3B) cancer cell lines.
The characteristics of apoptosis in cell morphology have been
observed using AO/EB and DAPI staining. The results attained
from the present compounds are of importance with respect to
the development of metal-based agents for anti-cancer
applications.Experimental section
Materials
All chemicals used in this study were reagent grade and were
used without further purication. Solvents were puried and
dried according to the standard procedures. All synthetic
manipulations were routinely performed under oxygen atmo-
sphere. Doubly distilled water was used to prepare buffers. Calf
thymus DNA (CT-DNA), bovine serum albumin (BSA), and 4-
nitrophenyl phosphate disodium salt hexahydrate (4-NPP) were
obtained from Genei, Bangalore and Himedia, India. Ethidium
bromide (EB), 3,5-di-tert-butylcatechol (3,5-DTBC), and tris(hy-
droxymethyl) amino methane were purchased from Sigma-
Aldrich and used as received. The synthesis of N,N-(dieth-
ylaminothiocarbonyl)benzimidoyl chloride was performed as
a multi-step synthesis by the standard procedure of Beyer et al.10
The reported method was used as for the synthesis of
primary amines such as 2-aminoacetophenone-N4-methyl-
thiosemicarbazone,25 except that the purication was carried
out by recrystallization from ethanol.General methods
Elemental analysis (C, H, N and S) was carried out on a Vario EL
III CHNS analyzer. Infrared spectra were obtained as KBr pellets
using a Perkin-Elmer FT-IR spectrophotometer in the range of
4000–400 cm1. 1H-NMR spectra were obtained on a Bruker
Ultra Shield at 300 MHz using CDCl3 as solvent and TMS as an
internal reference. Mass spectra for the complexes were ob-
tained on an advanced Q-TOFmicro™mass spectrometer using
an electrospray ionization probe. All MS results are given in the
form: m/z, assignment. Electronic spectra were obtained on
a JASCO V-570 spectrophotometer. ESR spectra were obtained
on a JEOL model JES FA200 ESR spectrometer at liquid nitrogen
temperature operating at X-band frequency (9.45 GHz). Geom-
etry optimization by the density functional theory (DFT) method
was performed using the B3LYP/6-311G package. Fluorescence
spectral data were obtained using a JASCO FP-8200 uorescence
spectrophotometer at room temperature. Single-crystal X-ray103338 | RSC Adv., 2015, 5, 103321–103342diffraction data collection was carried out at 100(2) K and
295(2) K on a Bruker Apex-II CCD area-detector equipped with
a liquid nitrogen cryostat. Melting points were checked on
a technico micro heating apparatus and are uncorrected. Stock
solutions of compounds (1.0  103 M in DMSO) were stored at
4 C and the required concentrations were prepared for all
experiments. All the stock solutions were used aer no more
than four days. Solutions of compounds were freshly prepared 1
hour prior to biochemical evaluation. Data were expressed as
the mean  the standard deviation from three independent
experiments.
Synthesis of ligand (H2L)
Solid N-(diethylaminothiocarbonyl)benzimidoyl chloride (1.018
g, 4 mmol) was added to a mixture of 2-aminoacetophenone-N4-
methylthiosemicarbazone (0.889 g, 4 mmol) and triethylamine
(1.01 g, 10 mmol) in 10 mL absolute ethanol. The mixture was
stirred for 2 h at 60 C. The organic solvent was evaporated
under reduced pressure to dryness. The residue was dissolved
in 20 mL of THF and brine solution (20 mL) was added. The
organic layer was separated, dried over MgSO4, ltered, and the
solvent was removed in vacuo. The residue was washed with
diethyl ether and dried under vacuum to give H2L as a pure
yellow solid. Single crystals suitable for X-ray determination
were grown by slow evaporation of an ethanol solution ofH2L at
room temperature.
Yield: 45% (0.616 mg). Color: yellowish orange; MP: 170 C;
micro analytical data for C22H28N6S2 required: C, 59.97; H, 6.40;
N, 19.07; S, 14.55%. Found: C, 59.65; H, 6.22; N, 19.46; S,
14.12%; IR (KBr, cm1): 3302, 3271, 3236 (NH), 1717, 1686, 1668
(C]N), 838, 781 (C]S). UV-vis [CHCl3, lmax, nm (3, dm
3 mol1
cm1)]: 238 (21 202), 280 (14 089). 1H NMR (300.13 MHz; CDCl3,
ppm): 1.22 (t, J ¼ 7.1 Hz, 3H, CH3), 1.24 (t, J ¼ 7.1 Hz, 3H, CH3),
1.28 (s, 3H, CH3), 3.20 (s, 3H, NCH3), 3.91 (q, J ¼ 7.1 Hz, 2H,
NCH2), 3.87 (q, J ¼ 7.1 Hz, 2H, NCH2), 7.16 (t, J ¼ 7.1 Hz, 2H,
Ph), 7.17–7.21 (m, 4H, Ph + C6H4), 7.36 (m, 3H, Ph + C6H4), 8.10
(s, 1H, NH), 8.47 (s, 1H, NH), 12.72 (s, 1H, NH). ESI-MS (calcd,
found, m/z) ¼ 440.63, 441.55 (M + H)+.
Synthesis of complexes 1 and 2
Ni(OAc)2$4H2O (0.2448 g, 0.001 mole) or Cu(OAc)2$4H2O
(0.1998 g, 0.001 mole) was dissolved in 20 mL of MeOH : CHCl3
(1 : 1, v/v) and the same solution of H2L (0.4406 g, 0.001 mol)
was added at room temperature. Aer the solution had been
continuously stirred for 30 min, three drops of Et3N in CH2Cl2
(5 mL) was added. The reaction mixture was stirred for 2 h at
room temperature. The reaction was monitored by thin-layer
chromatography (TLC) using silica gel on aluminium sheets
with a 10/90 mixture of ethyl acetate/petroleum ether as the
mobile phase. Aer completion of reaction, the resulting solu-
tion was ltered and the ltrate was le tranquil for the slow
evaporation of the mother solvent. Aer three days, large, black
colored crystals suitable for X-ray diffraction were obtained.
[Ni(L)] (1). Yield: 65%. Color: dark green; MP: 198 C; micro
analytical data for C22H26N6NiS2 required: C, 53.13; H, 5.27; N,
16.90; S, 12.90. Found: C, 53.01; H, 5.35; N, 16.36; S, 12.52%. IRThis journal is © The Royal Society of Chemistry 2015
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View Article Online(KBr, cm1): 3417 (NH), 1715 (C]N), 1527 (C]N), 1601 (C–N),
784 (C]S), 761 (C–S). UV-vis [CHCl3, lmax, nm (3, dm
3 mol1
cm1)]: 236 (13 924), 296 (8056), 367 (8132), 431 (7300). 1H NMR
(300.13 MHz, CDCl3, ppm): 1.28 (t, J¼ 7.2 Hz, 3H, CH3), 1.32 (t, J
¼ 7.2 Hz, 3H, CH3), 3.74 (d, J ¼ 5.0, 3H, NCH3), 3.76 (s, 3H, N]
C–CH3), 3.86 (m, 1H, NCH2), 3.89 (m, 1H, NCH2), 4.06 (m, 1H,
NCH2), 4.10 (m, 1H, NCH2), 4.85 (s, br, NH), 6.40 (d, J ¼ 8.0 Hz,
1H, C6H4), 6.78 (t, J ¼ 7.6 Hz, 1H, C6H4), 6.85 (t, J ¼ 7.7 Hz, 1H,
C6H4), 7.10 (m, 3H, Ph), 7.27 (d, J ¼ 7.2 Hz, 2H, Ph), 7.54 (d, J ¼
7.9 Hz, 1H, C6H4). ESI-MS (calcd, found, m/z) ¼ 497.31, 498.42
(M + H)+
[Cu(L)] (2). Yield: 60%. Color: dark brown; MP: 215 C; micro
analytical data for C22H26N6CuS2 required: C, 52.62; H, 5.22; N,
16.74; S, 12.77. Found: C, 53.22; H, 5.05; N, 16.36; S, 12.52%. IR
(KBr, cm1): 3390 (NH), 1700 (C]N), 1547 (C]N), 1572 (C–N),
790 (C]S), 764 (C–S). UV-vis [CHCl3, lmax, nm (3, dm
3 mol1
cm1)]: 237 (13 656), 298 (7800), 374 (7912), 491 (8176). ESR (X-
band, 9.45 GHz, LNT): gk 2.078, gt 2.031, gav 2.046. ESI-MS
(calcd, found, m/z) ¼ 502.06, 503.52 (M + H)+
X-ray structure determination
Suitable single crystals of H2L and complexes 1 and 2 were
mounted on a glass ber with epoxy cement. The crystals were
cut into a tting size (less than collimator cross section diam-
eter). Crystal data was obtained with a Bruker SMART APEX 2 at
100(2) K (H2L) and a Gemini A Ultra Oxford diffraction diffrac-
tometer at 295(2) K (complexes 1 and 2). The crystal data were
obtained using graphite monochromatized Cu (Ka, l ¼ 0.71073
A˚) for H2L and Mo (Ka, l ¼ 0.71073 A˚) for complexes 1 and 2
throughout. The data were corrected for Lorentz and polariza-
tion effects with the SMART14 suite programs and for absorp-
tion effects with SADABS.52 A data obtaining strategy using u
and 4 scans at 0.5 scan technique yielded full hemispherical
data with excellent intensity statistics. Structure solutions and
renements were performed using the program SHELXS-2014.53
The structures were solved by direct methods to locate the heavy
atoms, followed by difference maps for the light non-hydrogen
atoms. Anisotropic thermal parameters were rened for the rest
of the non-hydrogen atoms. Hydrogen atoms were placed
geometrically and rened isotropically. Details of the data
collection and renement are gathered in Table 1 and impor-
tant bond lengths and angles for the compounds are summa-
rized in Table 2.
Theoretical calculation (DFT)
All calculations were performed using the GAUSSIAN09 (G09)
program package with the aid of the Gauss View visualization
program. Full geometry optimizations of compounds were carried
out using the DFT method at the Becke's three parameter hybrid
exchange functional (B3LYP) level of theory while all the non-metal
atoms were described using the 6-311G basis set.54 This functional
has been shown to give more accurate results for all compounds.
Differences between the experimental and theoretical data were
determined for the solid and gas phases. Geometry optimizations
have been done without any symmetry restriction with X-ray
coordinates of the molecule. Frequencies of all complexes haveThis journal is © The Royal Society of Chemistry 2015been computed at the same level of theory to conrm that all
optimized structures are at true minima, which means they have
no imaginary frequencies. At the same level and basis sets,
calculations of the natural electron population, natural charge for
each atom and frontier molecular orbitals of the complexes have
been performed by natural bond orbital (NBO) analysis on the gas
phase optimized structures.55 The molecular orbital plots have
been generated using the chemcra program package (http://
www.chemcraprog.com).DNA-binding studies
Emissive titration. All the experiments concerning the
interaction of the complexes with calf thymus (CT) DNA were
performed in a mixed solvent of 5% DMSO and 95% Tris–HCl
buffer (5 mM Tris–HCl/50 mMNaCl buffer for pH 7.2) for all the
experiments, which was stored at 4 C for further use. Such
solutions, with the aqueous buffer DNA solutions used in the
studies, never exceeded 5% DMSO (v/v) in the nal solution,
which was needed due to the low aqueous solubility of most
compounds. All studies were performed at room temperature.
The solvent medium has no inuence on the compounds. The
CT-DNA concentration per nucleotide was determined uores-
cence spectrometry by selected compounds excitation wave-
length. During titration, an equal quantity of CT-DNA was
added to both the complex solution and the reference solution
to eliminate the intensity of CT-DNA itself and Tris–HCl buffer
was subtracted through base-line correction. Emissive titration
experiments were performed with a xed concentration of H2L
and complexes 1 and 2 (25 mM). While gradually increasing the
concentration (0–10 mM) of DNA, the emission intensities were
recorded for selected compounds in the range of 300–600 nm.
Titrations were manually done using a micropipette for the
addition of CT-DNA. It is noteworthy that the DNA in double
distilled water does not show any luminescence.
Ethidium bromide displacement assay. Ethidium bromide
displacement assays were carried out by the addition of H2L and
complexes 1 and 2 to a sample solution containing EB-DNA. The
spectra were obtained at an excitation wavelength of 500 nm over
an emission range of 605 nm. In the uorescence quenching
spectra, the reduction in emission intensity is a measure of the
binding propensity of the complex to CT-DNA. This displacement
method serves as indirect evidence to identify intercalative binding
modes. EB alone showed minimal uorescence, and the uores-
cence was enhanced greatly with gradual addition of CT-DNA until
maximum uorescence was achieved due to the formation of an
intercalative DNA–EB adduct. Addition of increasing amounts of
the compounds to the DNA–EB adduct quenched the uorescence.
Before the emission spectra were obtained, in these systems CT-
DNA was pretreated with EB in the ratio [DNA]/[EB] ¼ 1 : 1 ratio
for 30 minutes at room temperature to fully react. Then, the
titration compounds were added to this mixture of EB-DNA and
the change in the uorescence intensity was measured.
Viscosity experiment. Viscosity measurements were carried
out using an Ubbelodhe viscometer maintained at a constant
temperature of 30.0 C (0.1) in a thermostatic bath. DNA
samples of approximately 200 base pairs in length wereRSC Adv., 2015, 5, 103321–103342 | 103339
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View Article Onlineprepared by sonication to minimize complexities arising from
CT-DNA exibility. The ow time was measured three times,
aer 5 min of incubation, with each addition of H2L and
complexes 1 and 2 and the average ow time was taken for
calculation of relative viscosity. Relative viscosities for CT-DNA
in the presence and absence of the compound were calculated
from the relation g¼ (t to)/to, where t is the observed ow time
of a DNA-containing solution and to is the ow time of Tris–HCl
buffer alone. Data were presented as (h/h0)
1/3 versus binding
ratio (R ¼ [compounds]/[DNA] ¼ 0.0–0.1), where h is the
viscosity of CT-DNA in the presence of the compound and h0 is
the viscosity of CT-DNA alone.
Protein binding studies
Quenching of the tryptophan residues of BSA was performed
using H2L and complexes 1 and 2 as quenchers. The uores-
cence spectra were obtained at room temperature, with the
excitation wavelength of BSA at 280 nm and the emission at 344
nm, keeping the concentration of BSA constant (1 mM) while
increasing the complex concentration (0–50 mM) regularly. The
excitation and emission slit widths (each 5 nm) remained
constant for all the experiments. A scan rate of 500 nm min1
was used. In addition, absorption titration experiments were
carried out while keeping the concentration of the complexes
(20 mM) and the BSA concentration (1 mM) constant. Titrations
were manually done using a micropipette for the addition of
test compounds. The Stern–Volmer and Scatchard equations
and graphs were oen used to study the interaction of the
quencher with BSA.
Kinetic assays
Catechol oxidation. All kinetic experiments were carried out
under pseudo-rst-order conditions,56 with H2L and complexes
1 and 2 as the minor component. Quenching of the emission
intensity of 3,5-DTBC at lemis ¼ 437 nm (lex ¼ 401) was moni-
tored using the selected compounds. 100 equivalents of 1 
103 M solutions of 3,5-di-tert-butylcatechol (3,5-DTBC) in
DMSO were added to 1  104 M solutions of the selected
compounds in DMSO under aerobic conditions. The emissive
intensity of the resultant reaction mixture was plotted with
respect to wavelength at regular intervals of 15 min with
a spectrophotometer in the range of 400–700 nm.7 The depen-
dence of the rate on various concentration and different kinetic
parameters were obtained by treatment of 1  104 M solution
of compounds with 20 to 500 equivalents of substrate and
monitoring the upsurge in emission at 437 nm (the peak cor-
responding to the quinone band maxima) as a function of time.
Phosphate ester hydrolysis. Many metalloenzymes with
hydrolytic properties contain metal ions in close proximity to
the active site. The selected compound meets the prerequisites
for use as a functional model system for hydrolytic enzymes.
The disodium salt of 4-nitrophenylphosphate (4-NPP) was the
preferred choice of substrate. Its hydrolytic tendency was
detected spectrophotometrically by monitoring the time evolu-
tion of p-nitrophenolate57 in DMSO (lmax ¼ 436 nm) through
a wavelength scan from 400 to 600 nm over 2 hours. Quenching103340 | RSC Adv., 2015, 5, 103321–103342of the emission intensity of 4-NPP at 437 nm (excitation wave-
length at 401 nm) was monitored using H2L and complexes 1
and 2. Measuring the hydrolase activities involved the prepa-
ration of stock solutions of compounds (0.05  103 M) and the
substrate 4-NPP (1  103 M), at higher concentrations in pure
DMSO. The dependence of the rate on various concentration
and different kinetic parameters were obtained by treatment of
a 0.05  103 M solution of different compounds with 40
equivalents of substrate (the peak corresponding to the
phenolate band maxima) as a function of time.
MTT assay
Maintenance of cancer cell lines. The A375 (human malig-
nant melanoma skin cancer), HeLa (human cervical cancer),
and Hep3B (human hepatocellular carcinoma cancer) cell lines
were obtained from the National Centre for Cell Sciences
Repository, University of Pune, India. Normal Vero and A375,
HeLa and Hep3B cancer cells were maintained in a humidied
atmosphere containing 5% CO2 at 37 C in Dulbecco's modied
Eagle's medium (DMEM) supplemented with 100 units of
penicillin, 100 mg mL1 of streptomycin and 10% fetal bovine
serum (FBS). Briey, normal Vero and A375, HeLa, and Hep3B
cancer cells were precultured in 96-well microtiter plates for 48
h under 5% CO2.
Preparation of samples for cell line testing. The compounds
were dissolved in 0.1% DMSO (the concentration of DMSO did
not exceed 0.1% v/v) to obtain 1 mM solutions. The samples
were then diluted to 100 mM in PBS solution and lter-sterilized
using a 0.22 mm syringe lter. This 100 mM solution in PBS was
further used in cell cytotoxicity studies. The cells (1  106 cells
per mL per well) were seeded in a 96-well plate. One day aer
seeding, the cells were treated with or without different
concentrations of test compounds and re-incubated at 37 C in
a CO2 incubator for 24 h. Aer incubation, the cells were visu-
alized using an inverted Olympus microscope.
Protocol for MTT assay. The effect of the selected
compounds on the viability of Vero and A375, HeLa and Hep3B
cancer cell lines was determined using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The
selected compounds were added to the micro wells containing
the cell culture at nal concentrations in the range of 10–100 mg
mL1. Then, each well was loaded with 10 mL MTT solution (5
mg mL1 in PBS, pH ¼ 7.4) for 4 hours at 37 C. A purple for-
mazan crystal was dissolved in 200 mL DMSO and the cell
viability was determined by calculating the absorbance of each
well at 540 nm using a BIORAD ELISA plate reader.58 All data
were representative of three independent experiments and the
percentage cell viability was calculated according to the
following equation.
Inhibition rate (IR%) ¼ OD (control)  OD (drug treated cells)/
OD (control)  100.
The corresponding IC50 (concentration of drug that inhibits
cell growth by 50%) value was determined by nonlinear
regression analysis using Origin 6.0 soware.This journal is © The Royal Society of Chemistry 2015
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View Article OnlineFluorescence morphological investigation. Cellular
apoptotic morphological changes, which can be detected by AO/
EB and DAPI staining, were studied by uorescence microscopy.
The A375, HeLa and Hep3B cancer cells (1  106 in number)
were cultured in 6-well plates at 37 C in an incubator with xed
concentrations of complexes 1 and 2 (50 mM) for 24 h. The cells
were harvested and washed with ice-cold phosphate-buffered
saline (PBS) and 40 mL of AO/EB solution (1 part of 100 mg
mL1 of AO in PBS; 1 part of 100 mg mL1 of EB in PBS) was
added.59 Aer staining, the cells were washed with PBS twice,
suspended in 200 mL of PBS, and the nuclear morphology was
observed under a uorescence microscope aer less than 20
minutes. For DAPI staining, the treated cells were xed with
80% ethanol at room temperature for 30 min. The xative was
removed and the cells were washed 3 times with PBS before
incubating with DAPI (1 mg mL1) for 45 min at room temper-
ature in the dark. Both techniques were used to determine
viable cells, early apoptotic cells with blebbing, and necrotic
cells. Acridine orange intercalates into the DNA and gives
a green uorescence and thus the viable cells appear with
a green nucleus while early apoptotic cells show condensed or
fragmented nuclei. EB is taken up only by the non-viable cells
giving a bright orange nucleus of the dead cells overwhelming
the acridine orange stain.60 DAPI dye is effective for xed-cell
staining and quantication of DNA content. A375, HeLa and
Hep3B cancer cells were mounted on a slide, and the images
were observed under a uorescent microscope using a green/
blue lter with excitation at 350 nm and emission at 460 nm.
At least 200 cells from each slide were counted, and the
percentage of apoptotic cells was calculated on the basis of
cellular morphological features. The results were shown as the
mean of three independent experiments.Acknowledgements
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